ImmunityBio Inc (IBRX) concluded trading on Wednesday at a closing price of $2.76, with 5.25 million shares of worth about $14.49 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 3.37% during that period and on June 25, 2025 the price saw a loss of about -1.08%. Currently the company’s common shares owned by public are about 853.39M shares, out of which, 91.82M shares are available for trading.
Stock saw a price change of -2.82% in past 5 days and over the past one month there was a price change of 9.09%. Year-to-date (YTD), IBRX shares are showing a performance of -61.98% which increased to 7.81% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.83 but also hit the highest price of $7.48 during that period. The average intraday trading volume for ImmunityBio Inc shares is 9.34 million. The stock is currently trading -5.40% below its 20-day simple moving average (SMA20), while that difference is up 3.03% for SMA50 and it goes to -17.32% lower than SMA200.
ImmunityBio Inc (NASDAQ: IBRX) currently have 853.39M outstanding shares and institutions hold larger chunk of about 9.08% of that.
The stock has a current market capitalization of $2.44B and its 3Y-monthly beta is at -0.01. It has posted earnings per share of -$0.58 in the same period. It has Quick Ratio of 2.05. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for IBRX, volatility over the week remained 2.36% while standing at 4.60% over the month.
Analysts are in expectations that ImmunityBio Inc (IBRX) stock would likely to be making an EPS of -0.1 in the current quarter, while forecast for next quarter EPS is -0.11 and it is -0.27 for next year. For the current quarter EPS, analysts have given the company a lowest target -0.12 which is -0.09 at the higher side of the target for the same. Stock’s fiscal year EPS is expected to rise by 23.85% while it is estimated to increase by 37.73% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Piper Sandler on May 20, 2025 offering an Overweight rating for the stock and assigned a target price of $5 to it. Coverage by H.C. Wainwright stated ImmunityBio Inc (IBRX) stock as a Buy in their note to investors on March 06, 2025, suggesting a price target of $8 for the stock. On January 10, 2025, BTIG Research Initiated their recommendations, while on May 12, 2023, Piper Sandler Downgrade their ratings for the stock with a price target of $4. Stock get a Buy rating from Jefferies on August 03, 2022.
